Sensydia raises funds to commercialise CPS cardiac assessment platform
/The CPS platform has been designed to provide quick, safe and non-invasive cardiac performance assessment.
Sensydia has raised nearly $8m in a financing round for advancing its cardiac performance system (CPS) platform.
Led by Florida-based Orlando Health Ventures, the financing round saw participation from Frontier Venture Capital, Colle Capital and other investors.
Sensydia intends to use the funds to prepare for the commercialisation of CPS, the next-generation haemodynamic monitoring platform.
Sensydia president and CEO Anthony Arnold said: “We are thrilled to have the support of investors who share our vision for transforming heart failure management.
“This funding will enable us to accelerate our march to commercialisation by expanding development and operations for our CPS platform.”